Pain: Current Understanding of Assessment, Management, and Treatments

This program is supported by an unrestricted educational grant from NPC. For permission to reprint any of the copyrighted materials herein, contact NPC at (703) 620-6390 or www.npcnow.org.
Editorial Advisory Board

Patricia H. Berry, PhD, APRN, BC, CHPN
Assistant Professor
College of Nursing
University of Utah
Salt Lake City, UT

Edward C. Covington, MD
Director, Chronic Pain Rehabilitation Program
Cleveland Clinic Foundation
Cleveland, OH

June L. Dahl, PhD
Professor of Pharmacology
University of Wisconsin School of Medicine and Public Health
Madison, WI

Jeffrey A. Katz, MD
Associate Professor of Anesthesiology
Director, Pain Clinic VAHCS, Lakeside Division
Northwestern University Medical School
Chicago, IL

Christine Miaskowski, RN, PhD, FAAN
Professor
Department of Physiological Nursing
University of California
San Francisco, CA

The material presented in this continuing education program represents the opinions of the editorial advisory board and not the views of the American Pain Society.
Disclosures

It is the policy of the American Pain Society that planners and faculty disclose the existence of any significant financial interest or other relationships they may have with the manufacturer(s) of a commercial product(s) or services relating to the topics presented in an educational activity over which they have control. When unlabeled uses are discussed, these will also be disclosed.

This continuing education activity includes the discussion of unlabeled uses in the following areas:

Section III.A.2.c. Antiepileptic drugs on pages 38 and 45 and Table 25 on page 43
Section III.A.2.d Antidepressants on pages 45-46 and Table 25 on page 43
Section III.A.2.f Other on page 47
Section IV.B.3.a Pharmacologic management (pages 66-67 and Table 37 on page 66)
Section IV.B.4 Management of Some Common Types of Chronic Noncancer Pain, Tables 39 and 40 on pages 68 and 69
CE test questions 22-25 on page 98 and 31-32 on page 99

Most uses of antiepileptic drugs for providing analgesia (pages 38, 42, 43, 45, 50, 66, 67, 68, and 69) are unapproved in this monograph.

Gabapentin (Neurontin) is indicated for postherpetic neuralgia (and seizure disorders).

Carbamazepine (Tegretol) is indicated for trigeminal neuralgia and glossopharyngeal neuralgia (and epilepsy).

Divalproex sodium (Depakote) is indicated for migraine headache prophylaxis (and mania and epilepsy).

Phenytoin (Dilantin) is indicated only for epilepsy.

Antidepressants are not approved for pain management. The use of tricyclic antidepressants for migraine prophylaxis and postherpetic neuralgia (pages 43, 45, 46, 47, 66, 67, 68, and 69) are unapproved uses. The footnote on page 45 about the use of SSRIs for providing analgesia is an unapproved use.

Eutectic Mixture of Local Anesthetics (lidocaine and prilocaine) (EMLA®) (page 44) is indicated as a topical anesthetic for use on (1) normal intact skin for local analgesia and (2) genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia (postherpetic neuralgia and other neuropathic pain in Table 25 are unapproved uses).

Edward C. Covington, MD
Sources of Funding for Research
None
Current Consulting Agreements
Eli Lilly & Company
Pfizer Inc.
Purdue Pharma L.P.
Current Financial Interests/Stock Ownership
None
Speaker's Bureau
None

June L. Dahl, PhD
Sources of Funding for Research
Medtronic Foundation
Purdue Pharma L.P.
Current Consulting Agreements
None
Current Financial Interests/Stock Ownership
None
Speaker's Bureau
None

Jeffrey A. Katz, MD
Sources of Funding for Research
None
Current Consulting Agreements
None
Current Financial Interests/Stock Ownership
None
Speaker's Bureau
None

Christine Miaskowski, RN, PhD, FAAN
Sources of Funding for Research
Endo Pharmaceuticals
Janssen Pharmaceuticals
Purdue Pharma L.P.
Current Consulting Agreements
Cephalon, Inc.
Endo Pharmaceuticals
Merck & Co., Inc.
Ortho-McNeil Pharmaceutical, Inc.
Current Financial Interests/Stock Ownership
None
Speaker's Bureau
Cephalon, Inc.
Eli Lilly and Company
Endo Pharmaceuticals
Merck & Co., Inc.
Ortho-McNeil Pharmaceutical, Inc.

Patricia H. Berry, PhD, RN, CHPN, CS
Sources of Funding for Research
None
Current Consulting Agreements
None
Current Financial Interests/Stock Ownership
None
Speaker's Bureau
Purdue Pharma L.P.
**Target Audience/Learning Objectives**

The target audience for this activity includes pain specialists, primary care providers, neurologists, psychiatrists, psychologists, nurses, nurse practitioners, and pharmacists. After reading this monograph, the participant should be able to:

1. Describe the current status of pain management in the United States, barriers to appropriate assessment and management of pain, and consequences of undertreatment of pain.
2. Explain the pathophysiologic mechanisms involved in pain perception.
3. Name elements of the pain assessment process, a tool used for pain assessment, and strategies for overcoming barriers to pain assessment.
4. List the types of pharmacotherapies used to manage pain and compare the mechanisms of action, uses, dosage forms, routes of administration, dosages, and side effects of the various options.
5. Discuss the role of nonpharmacologic interventions in treating pain and name a clinical use for a nonpharmacologic treatment.

**Continuing Education**

This activity is no longer being offered for continuing education credit. It is available here as a resource for pain professionals' use.
# Table of Contents

## Section I: Background and Significance

A. Introduction ........................................................................................................ 3

B. Definitions and Mechanisms of Pain ................................................................. 4
   1. What Is Pain? .................................................................................................... 4
   2. How Does Injury Lead to Pain? ................................................................... 4
   3. What Happens During Transduction? ............................................................. 5
   5. What Is Perception? .................................................................................... 7
   7. What Is Peripheral Sensitization? ................................................................. 8
   8. What Is Central Sensitization? .................................................................. 8
  10. What Is Neuropathic Pain? ......................................................................... 10

C. Classification of Pain ..................................................................................... 10
   1. Acute Pain .................................................................................................. 10
   2. Chronic Pain .............................................................................................. 11
   3. Cancer Pain ............................................................................................... 11
   4. Chronic Noncancer Pain ........................................................................... 12

D. Prevalence, Consequences, and Costs of Pain ............................................. 13
   3. What Are the Consequences and Costs of Under-treatment of Pain? ... 14

E. Barriers to the Appropriate Assessment and Management of Pain .......... 15
   1. Barriers Within the Health Care System .................................................... 15
   2. Health Care Professional Barriers .............................................................. 16
   3. Patient and Family Barriers ....................................................................... 16
   4. Legal and Societal Barriers ....................................................................... 17
   5. Tolerance, Physical Dependence, and Addiction ....................................... 17

## Section II: Assessment of Pain....................................................................... 19

A. Initial Assessment of Pain .............................................................................. 21
   1. Overcoming Barriers to Assessment ......................................................... 21
   2. Goals and Elements of the Initial Assessment ........................................... 21

B. Measurement of Pain: Common Assessment Tools .................................. 25
   1. Unidimensional Scales ............................................................................. 25
   2. Multidimensional Tools ........................................................................... 26
   3. Neuropathic Pain Scale ............................................................................. 29

C. Reassessment of Pain ................................................................................... 29
   1. Frequency .................................................................................................... 29
   2. Scope and Methods ................................................................................... 29